Market News AIOpen the app

Alamar Biosciences shared its Q3 2026 earnings, showing a 68% rise in sales.

ResultsRead the original at Benzinga
Good for ALMR

Alamar's Q3 sales rose 68% year over year, consumables sales grew 79%, and the share of sales left after direct product costs reached 61.5%. It also raised its full-year sales forecast.

ALMR · Alamar Biosciences

AI read · Good for ALMR

The AI's read

Consumables drove much of the growth, so sales are coming from products customers use with Alamar’s platform, not only from new instrument placements. UK Biobank and GSK also selected Alamar for large studies, though those choices do not guarantee future orders. The clinical instrument filing is planned for the end of 2027. Current sales growth and improved product margins matter more today.

Get alerts for ALMR

Follow Alamar Biosciences (ALMR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALMR
Free on the App Store and Google Play, or on the web.